The plan to develop foam/gel/pill formulation tell

The plan to develop foam/gel/pill formulation tells me that the cohort 3 data observed so far must be positive. UC and CD are where the big money is, but IPIX doesn't have the technology to deliver B to the affected locations using pills. Luckily management have identified BPs with such technology but lack drugs, which makes them perfect partners. From Dr. B,

Quote:

---

Yes, absolutely you're right on target with that and I think as I mentioned earlier, half of inflammatory bowel disease or more is Crohn's disease and Crohn's disease can happen anywhere in the GI tract. It's not just at the distal end like in the ulcerative colitis where we're getting the exciting results.

So, I think based on the results that we've gotten so far that we can get the drug into the GI tract without getting very much in the way of systemic absorption, it's an obvious direction that we would want to go to try to formulate a pill delivery.

So, it could treat throughout the GI tract and the technology for those kinds of deliveries have really gotten quite impressive in recent years that you can actually target certain areas of the GI tract where you can get pills to provide the active pharmaceutical ingredient to come out of the pill housing.

So, I think it would not be reinventing the wheel on how to do that. A lot of big pharms right now understand that themselves. Some actually have the technology available, but maybe lacking in terms of the right drug candidate with enough horsepower to treat the disease.

So that really just sets us up as Leo mentioned again toward a partnership. If that's appreciated, I think we could be in very good shape to move that in that direction without having to reinvent the wheel and really coming across the finish line effectively.

---

https://seekingalpha.com/article/4080068-inno...art=single

If that's not enough of a hint for a partnership, here's Dr. B again.

Quote:

---

Brilacidin’s unique multi-pronged ability to reduce inflammation, fight infection and heal GI tract mucosa has been impressive, based both on subjective and objective scoring measures. It’s no surprise to us why we’ve generated significant excitement regarding Brilacidin among patients, health care professionals and potential industry partners interested in this truly novel IBD drug candidate.

---

http://www.ipharminc.com/press-release/2017/6...ly-13-2017